NEW YORK – QuantuMDx said Monday that it has recently closed a $14 million financing round consisting of a mix of debt and ordinary equity.
The firm said it will use the funds, which were supported by existing shareholders, to support progress toward the commercial launch of its Q-POC high-risk HPV genotyping assay, planned for early 2021.
The Newcastle upon Tyne, UK-based company said that it has started the CE mark approval process of commissioned Q-POC devices and expects to certify them in the first half of this year.